GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (OTCPK:SHPGF) » Definitions » Operating Margin %

Shire (SHPGF) Operating Margin % : 26.77% (As of Sep. 2018)


View and export this data going back to . Start your Free Trial

What is Shire Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Shire's Operating Income for the three months ended in Sep. 2018 was $1,036 Mil. Shire's Revenue for the three months ended in Sep. 2018 was $3,872 Mil. Therefore, Shire's Operating Margin % for the quarter that ended in Sep. 2018 was 26.77%.

The historical rank and industry rank for Shire's Operating Margin % or its related term are showing as below:


SHPGF's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -177.195
* Ranked among companies with meaningful Operating Margin % only.

Shire's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Shire's Operating Income for the three months ended in Sep. 2018 was $1,036 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2018 was $4,066 Mil.


Shire Operating Margin % Historical Data

The historical data trend for Shire's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shire Operating Margin % Chart

Shire Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.43 35.53 24.04 17.13 22.41

Shire Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.73 25.85 24.94 25.98 26.77

Competitive Comparison of Shire's Operating Margin %

For the Biotechnology subindustry, Shire's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shire's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shire's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Shire's Operating Margin % falls into.



Shire Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Shire's Operating Margin % for the fiscal year that ended in Dec. 2017 is calculated as

Operating Margin %=Operating Income (A: Dec. 2017 ) / Revenue (A: Dec. 2017 )
=3397.2 / 15160.6
=22.41 %

Shire's Operating Margin % for the quarter that ended in Sep. 2018 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2018 ) / Revenue (Q: Sep. 2018 )
=1036.4 / 3871.7
=26.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shire  (OTCPK:SHPGF) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Shire Operating Margin % Related Terms

Thank you for viewing the detailed overview of Shire's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Shire (SHPGF) Business Description

Traded in Other Exchanges
N/A
Address
Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.